Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CDW Corp. (CDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs CDW Corp. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.07 (market cap $29.60B), while CDW Corp. trades at $136.89 (market cap $16.92B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and CDW Corp. pays a 1.86% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CDW | |
|---|---|---|
Market Cap | $29.60B | $16.92B |
Sector | Health | Technology |
52-Week High | $491.22 | $170.77 |
52-Week Low | $205.48 | $99.30 |
Enterprise Value | $27.56B | $22.52B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
CDW trades at $135.79, down 0.47% on the day, with a bearish technical signal. The stock shows strong profitability with a 44.01% ROE and trades at a P/E of 16.27. Recent Q2 2026 earnings beat expectations with EPS of $2.91, driven by 10% revenue growth, though margin pressures were noted. Analyst consensus is bullish with a $148.67 price target. The company maintains a solid balance sheet with a debt-to-asset ratio of 39.8% as of 2024.
The outlook for CDW is positive due to AI and infrastructure demand, but margin compression and a CFO transition in 2027 pose risks. Upside potential exists if the company meets Q3 2026 EPS expectations of $2.91 and sustains revenue growth. Key risks include competitive pressures and macroeconomic volatility affecting IT spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →
